MedPath

Target Controlled Infusion of Etomidate or Propofol for Anesthesia of Thoracoscopic Mitral Valve Replacement Surgery

Phase 4
Conditions
Hemodynamic Instability
Delirium
Interventions
Device: Bispectral Index Monitor
Drug: Induction of anesthesia
Drug: Maintenance of anesthesia
Other: Tracheal Intubation
Registration Number
NCT02644980
Lead Sponsor
Xijing Hospital
Brief Summary

For patients requiring the heart valve replacement surgery, heart function is injured in different degree.Thus, minimizing the impact of the anesthesia drug on the cardiovascular system has important clinical meanings. Etomidate has slight effect on the cardiovascular system, often used in the induction of anesthesia, however target controlled infusion etomidate in maintenance of anesthesia is less used. So, the trial is designed to observe the application value of TCI etomidate in thoracoscopic mitral valve replacement surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
110
Inclusion Criteria
  1. Age 18~75 years old
  2. Selective cardiopulmonary bypass thoracoscopic mitral vales replacement surgery
  3. Received heart surgery for the first time
  4. New York Heart Association(NYHA) II~III
  5. Written informed consent -
Exclusion Criteria
  1. Emergency surgery
  2. Anticipated survival time <1 yrs
  3. Serious heart, brain, liver,kidney,lung,endocrine diseases or serious infection
  4. Prolonged use of hormone or history of adrenal suppression disease
  5. Severe mediastinal fiber thickening or fibrous adhesions
  6. Allergy to experimental drug or other contraindications
  7. Occurred or expected occurring of difficulty airway
  8. Sure or suspected narcotic analgesics abuse
  9. History of neuro-muscular disease
  10. Mental instability or metal disease
  11. Pregnancy or brest-feeding
  12. Participated other clinical trial past 30 days
  13. Malignant hyperthermia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PropofolPropofolThe initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
EtomidateMaintenance of anesthesiaThe initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
EtomidateTracheal IntubationThe initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
PropofolInduction of anesthesiaThe initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
EtomidateBispectral Index MonitorThe initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
PropofolMaintenance of anesthesiaThe initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
PropofolTracheal IntubationThe initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
EtomidateInduction of anesthesiaThe initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
PropofolBispectral Index MonitorThe initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
EtomidateEtomidateThe initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
Primary Outcome Measures
NameTimeMethod
Blood pressurefrom the beginning of induction to the surgery over, up to 6 hrs.

blood pressure(systolic blood pressure and diastolic blood pressure) is monitored and recorded at 9 time points, including 10 minutes before induction,the right moment after induction of anesthesia and tracheal intubation,the beginning of surgery and the cardiopulmonary bypass(CPB),the time the ascending aorta is blocked and unstuck,the time the CPB and the surgery is over.

Secondary Outcome Measures
NameTimeMethod
Heart ratefrom the beginning of induction to the surgery over, up to 6 hrs.

Heart rate is monitored and recorded at 9 time points, including 10 minutes before induction,the right moment after induction of anesthesia and tracheal intubation,the beginning of surgery and the cardiopulmonary bypass(CPB),the time the ascending aorta is blocked and unstuck,the time the CPB and the surgery is over.

DeliriumThe right moment of patients'leaving off PACU, expected to be 2 h from the end the of operation

Using Confusion Assessment Method for the Intensive Care Unit(CAM-ICU) to screening of delirium.

Life qualityat the time of one month right after the surgery

using the Activities of Daily Living (ADL) to assess the life quality one month after the surgery.

Number of Participants with Serious and Non-Serious Adverse EventsUp to 1 month

Number of Participants with Serious and Non-Serious Adverse Events including major adverse cardiovascular and cerebrovascular event such as cardiac infraction,stroke, acute renal failure, re-surgery,and death.

Safety Issue?: Yes

Time of recovery from anesthesiafrom the time TCI is stopped to the time patients' eyes open after the surgery, up to 30 minutes.
Bispectral index (BIS) valuefrom the beginning of induction to the surgery over, up to 6 hrs.

BIS is monitored and recorded at 9 time points, including 10 minutes before induction,the right moment after induction of anesthesia and tracheal intubation,the beginning of surgery and the cardiopulmonary bypass(CPB),the time the ascending aorta is blocked and unstuck,the time the CPB and the surgery is over.

onset timeThe time from TCI etomidate or propofol to the disappearance of eyelash reflex,up to 10 minutes.

The time period from TCI etomidate or propofol to the disappearance of eyelash reflex.

© Copyright 2025. All Rights Reserved by MedPath